<DOC>
	<DOC>NCT02318329</DOC>
	<brief_summary>This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.</brief_summary>
	<brief_title>Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>Part 1A is a dose-escalation study in patients with any locally advanced or metastatic solid tumor or lymphoma for which standard therapies have been exhausted. Part 1B will further assess safety and evaluate PK of FPA144 in gastric cancer patients. Part 2 patients will be enrolled and treated in order to further characterize safety and preliminary efficacy in a selected cancer patient population with the greatest potential for clinical benefit from FPA144 treatment.</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Life expectancy of at least 3 months ECOG performance status of 0 to 1 Adequate hematological and organ function, confirmed by lab values Tumor tissue for determination of FGFR2b overexpression and FGFR2 amplification (optional for Part 1A patients) QTc segment &gt;470 msec Treatment with any anticancer therapy or investigational drugs &lt;/=14 days (&lt;/=28 days for patients in Korea) prior to first dose of FPA144 Presence of any condition that may increase the risk associated with study participation or interfere with interpretation of study results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>FGFR2b, FGFR2, FGFR, bladder neoplasms, esophageal cancer</keyword>
</DOC>